FDA Cybersecurity Guidance: What Medical Device Teams Should Prepare For

FDA cybersecurity guidance affects medical device security planning by making cybersecurity a lifecycle concern, not a final checklist before release. Teams need to consider how a device connects, how threats could affect safety and essential performance, how risks will be tested and documented, and how vulnerabilities will be handled after deployment. The exact obligations depend on the device and its regulatory pathway, so use current FDA materials and qualified regulatory advice for decisions.

Review medical device security testing options

What does FDA cybersecurity guidance mean for device planning?

FDA cybersecurity guidance is relevant to manufacturers whose devices include software, network connectivity, or other features that create cybersecurity risk. The core planning implication is to connect security work with device risk management and patient safety. A vulnerability is not only an IT issue if exploitation could disrupt a clinical function, expose sensitive data, or affect a device’s essential performance.

Guidance should be read alongside applicable laws, regulations, recognized standards, and the device’s specific submission requirements. It is not a universal testing recipe, and a penetration test alone does not establish compliance. Instead, teams should build a defensible process: identify the system and its dependencies, assess threats and impacts, implement controls, verify those controls, and maintain a plan for new issues.

For broader context, see Penti’s guide to medical device penetration testing and its healthcare application security priorities.

When should cybersecurity enter the development process?

Start during concept and architecture work, before design choices become expensive to change. Early review helps teams identify trust boundaries, external interfaces, third-party components, and functions whose compromise could affect patient care. Keep cybersecurity activities connected to product risk management and design controls rather than assigning them only to a late-stage test team.

• Concept and requirements: define intended use, operating environments, users, data flows, and security objectives.
• Architecture: map interfaces, accounts, cloud services, mobile apps, update mechanisms, and dependencies.
• Implementation: use secure development practices, review changes, and track software components and known issues.
• Verification: test security requirements and investigate whether controls work under realistic conditions.
• Release and postmarket: document residual risk, establish vulnerability intake and response, and reassess when the product or threat context changes.

For example, suppose a product team adds a remote maintenance feature late in development. That change can introduce a new identity path, network exposure, and supplier dependency. The team should update the system diagram and threat scenarios, define authentication and authorization expectations, and determine what verification is needed before concluding that existing evidence still applies. A changed interface can invalidate assumptions made by an earlier assessment.

This sequence is not a fixed FDA-mandated checklist for every product. It is a practical way to keep decisions traceable and cybersecurity work proportionate to the device’s architecture and risk.

How should teams scope the device and its attack surface?

Define the system boundary broadly enough to include the pieces that can affect device security or safety. A connected device may rely on firmware, a companion application, cloud services, identity providers, hospital networks, update infrastructure, and vendor libraries. Leaving a dependency out of scope can hide a meaningful path into the device or its data.

Build an inventory and data-flow view that answers practical questions:

• Which components store, process, or transmit sensitive or safety-relevant data?
• Which interfaces are exposed locally, over a network, or through a cloud service?
• How do clinicians, administrators, service technicians, and patients authenticate?
• How are software updates delivered, validated, and rolled back?
• Which suppliers provide software, hosting, connectivity, or support?
• What happens if a key service is unavailable or an account is compromised?

Make the inventory useful by recording an owner, version, purpose, data handled, and connection for each significant component. For a cloud service, note what the device sends, what response it trusts, and how the service is authenticated. For an update channel, document signing and validation steps, who can authorize a release, and how failed installation is handled. These details help reviewers ask concrete questions rather than treating “cloud” or “firmware” as a complete scope description.

Map components to intended use and operating conditions. A device used in a controlled clinical network may still encounter remote support channels, shared workstations, mobile connectivity, or misconfigured integrations. Document assumptions and verify them with product, engineering, clinical, and operations stakeholders. If a deployment assumption is that the hospital isolates a network segment, record who is responsible for that control and what happens when the assumption is not met.

How can threat modeling connect cyber risk to patient safety?

Threat modeling helps teams move from a list of components to plausible attack scenarios. Begin with assets and trust boundaries, then consider threat actors, entry points, weaknesses, and outcomes. For each scenario, ask whether the result could affect confidentiality, integrity, availability, clinical workflow, or essential performance.

For example, a threat scenario could involve an attacker abusing a weakly protected service interface to alter a configuration. Identify safeguards that prevent unauthorized access, how the change would be detected, and whether the device can fail safely or recover. The point is not to assume every scenario is equally likely; it is to make reasoning explicit and test the controls that matter.

A useful scenario record is concise but complete: describe the component and entry point, the attacker’s required access, the action attempted, the possible technical and clinical effects, existing safeguards, and remaining uncertainty. Then connect each mitigation to a verification activity. If a control is intended to prevent unauthorized configuration changes, for instance, test both the expected authorized workflow and plausible unauthorized attempts. Record what was in scope and what limitations affected the test.

Record assumptions, severity rationale, mitigations, and residual risks. Revisit the model when functionality, connectivity, suppliers, deployment environments, or vulnerability information changes. Penti’s attack surface management guide offers ideas for keeping asset and exposure views current.

What should security verification include?

Verification should be selected from the device’s architecture and risk analysis, not from a generic checklist alone. Different methods answer different questions. Code analysis can reveal implementation weaknesses; configuration review can identify unsafe settings; vulnerability assessment can locate known exposures; and penetration testing can evaluate whether selected attack paths are practically exploitable in the agreed environment.

Medical device tests need explicit safety boundaries. Identify prohibited actions, test windows, permitted environments, backup and recovery expectations, and escalation contacts before work begins. A production-connected device or live clinical service should not be probed without authorization and a risk-appropriate plan. If direct testing could disrupt essential functions, use a representative environment or another suitable verification method.

Plan the test around specific questions. A configuration review might check whether unused services are disabled and whether access is restricted to intended roles. A vulnerability assessment may identify known exposures but will not necessarily show whether a weakness can be reached in the deployment context. A penetration test can examine a defined attack path, but its findings are limited by the scope, test conditions, and time available. Use the method whose evidence answers the risk question, and state what it does not establish.

Testing should reflect the full system where relevant. Web interfaces, APIs, cloud components, mobile applications, and network services may expose different risks. See Penti’s guides to API security testing and types of penetration testing when planning coverage across connected components.

What evidence should teams retain?

Useful documentation lets reviewers understand what was evaluated, why the scope was chosen, what was found, and how the team responded. Organize records so conclusions can be traced to product versions and risk decisions. Do not rely on a test report alone to tell the full security story.

• System diagrams, interface inventories, and relevant software component records.
• Threat scenarios, risk assessments, assumptions, and control rationale.
• Test scope, methods, dates, environments, limitations, and authorization.
• Findings with reproducible evidence, affected versions, severity rationale, and remediation status.
• Retest results and documented disposition of unresolved issues.
• Vulnerability monitoring, coordinated response, customer communication, and update procedures.

Evidence should be consistent with the product’s current configuration. A report for an earlier build may not support conclusions about a materially changed release. Maintain version identifiers and explain which changes trigger additional review or testing.

Think of the evidence chain as a set of linked records rather than a folder of unrelated files. A risk scenario should point to its control, the control to its verification, and a finding to its remediation and retest. If a reviewer asks why an issue was accepted, the record should show who made the decision, which information was considered, and why the remaining risk was judged acceptable under the team’s process. This structure also helps engineering teams avoid repeating analysis when a similar change appears in a later release.

How should teams plan for postmarket cybersecurity?

Release does not end cybersecurity responsibility. Establish a process for receiving vulnerability reports, evaluating affected products, prioritizing remediation, preparing updates, and communicating with relevant stakeholders. Assign an owner for each step and define how decisions are escalated when a vulnerability could affect safety or device availability.

Postmarket planning should connect monitoring with action. Track applicable vulnerability information for software and suppliers in use. When an issue appears, determine whether the product is affected, assess exposure and potential impact, identify mitigations, and document the decision. If a correction or update is needed, consider installation constraints and how users will be informed.

Consider a report about a library used by a companion service. The response owner first checks whether the affected version is present in the product and whether the vulnerable feature is enabled. Engineering then evaluates reachable paths and relevant safeguards, while quality and regulatory stakeholders assess impact and required actions. If an update is prepared, test it against the affected configuration, document the release decision, and provide clear deployment information. This sequence makes triage actionable without assuming every alert has the same relevance.

Keep the process practical: teams need clear intake channels, response roles, decision records, update validation, and a way to confirm the issue is addressed. Penti’s software supply chain security guide can help teams think through dependency visibility and supplier-related exposure.

How do requirements differ across products?

There is no single cybersecurity plan that fits every medical device. Product type, intended use, connectivity, software architecture, submission pathway, and potential patient impact all shape the work. Teams should confirm which current FDA recommendations and applicable requirements fit their product, then align engineering, quality, regulatory, clinical, and security stakeholders on the evidence needed.

These questions can help organize a planning meeting, but they do not determine a regulatory pathway. A device with no network interface may present a different set of cyber risks than a connected system with remote access, cloud processing, and frequent updates. Likewise, a change in intended use or deployment context can change the analysis. The team should record why particular risks and verification activities are relevant, not merely copy a template from another product.

FDA materials and submission expectations can change, so check the current official source before making a regulatory decision. The available research article, Cybersecurity requirements for medical devices in the EU and other regions, discusses regulatory guidance in the EU, not FDA requirements. Treat it only as comparative context, not as a source of FDA obligations.

What should a team do first?

A focused first cycle can create a sound basis for later planning:

1. Identify the product, intended use, versions, interfaces, and connected dependencies.
2. Bring security, engineering, quality, regulatory, clinical, and operations owners together to agree on boundaries and assumptions.
3. Map a small set of credible threat scenarios to safety, privacy, and availability impacts.
4. Select verification activities that address the highest-priority risks, with clear authorization and safety controls.
5. Document findings and decisions, assign remediation owners, and verify fixes against the relevant version.
6. Set a repeatable cadence for reviewing changes, vulnerability reports, suppliers, and postmarket response.

Make the first cycle bounded. For example, choose one product configuration and one high-priority interface, then trace a scenario from entry point through possible impact, safeguards, test evidence, and any open action. This is more useful than attempting a broad review without stable scope or owners. Once the first loop is complete, agree what must change before expanding to other configurations or interfaces.

For development teams, connect the work with existing change review. A new dependency, authentication mechanism, remote access path, or update process can trigger a focused reassessment. For quality and regulatory staff, define where the rationale and evidence live and who reviews it. For security teams, make sure test reports identify the product build and environment, so findings can be acted on rather than detached from the release process. Penti’s DevSecOps workflow guide discusses ways to connect security activities with development processes.

Frequently Asked Questions

Does FDA cybersecurity guidance require every device to have a penetration test?

Do not assume one testing method applies identically to every product. Verification should reflect the device, its risks, architecture, and applicable regulatory context. Confirm current FDA materials and product-specific expectations with regulatory specialists.

Is a penetration test enough to demonstrate cybersecurity readiness?

No. A test is one source of evidence. Teams also need a defined system scope, risk analysis, control rationale, remediation records, and a plan for vulnerability response after release.

Can teams test a device while it is in clinical use?

Testing in a live clinical environment can create operational or safety risks. Define authorization and boundaries in advance, and use a representative test environment or alternative methods when direct testing is not appropriate.

How often should a device be reassessed?

Set reassessment triggers based on product changes, new vulnerabilities, supplier updates, deployment changes, and the team’s risk process. A fixed schedule can help, but it should not replace review when a material change or new concern arises.

Explore healthcare application security considerations

FDA cybersecurity guidance is most useful when teams translate it into documented, device-specific decisions across design, verification, release, and postmarket response. Keep the work grounded in patient safety, current regulatory advice, and evidence that reflects the product being deployed.